Published evidence for MaiLi
Journal of Clinical and Cosmetic Dermatology ISSN 2576-2826 | Open Access
Sci Forschen Open HUB for Scientific Research
This article present preliminary safety and efficacy data from the first private patient series treated with the first patented OxiFree ™ technology cross-linked hyaluronic acid gel – MaiLi.
RESEARCH ARTICLE A Preliminary Report on the Safety and Efficacy of a Novel MaiLi HA Filler for Facial Correction of Wrinkles, Folds, Volume and Lips Patrick Micheels 1, *, and Mickaël Poiraud 2 Volume 7 - Issue 1
1 Private office, Chemin de la Fontaine, Chêne-Bougeries, Switzerland 2 Clinique de la Croix d’Or, ASLAN Medical SA, Geneva, Switzerland
*Corresponding author: Patrick Micheels, Private office, Chemin de la Fontaine, Chêne-Bougeries, Switzerland, Tel: +41(0)223471113; E-mail: patrickscab@bluewin.ch
Received: 13 Dec, 2022 | Accepted: 12 Jan, 2023 | Published: 18 Jan, 2023
Citation: Micheels P, Poiraud M (2023) A Preliminary Report on the Safety and Efficacy of a Novel MaiLi HA Filler for Facial Correction of Wrinkles, Folds, Volume and Lips. J Clin Cosmet Dermatol 7(1): dx.doi.org/10.16966/2576-2826.175 Copyright: © 2023 Micheels P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: The principal author was given the opportunity to assess new hyaluronic acid filler, first before its European Commission labeling during clinical investigations in France, and then after its European Commission labeling in his clinical practice in Geneva, Switzerland. This hyaluronic acid gel benefits from the world’s first patented OxiFree™ technology. This article sought to present preliminary safety and efficacy data from the first private patient series treated in Geneva with this cross-linked hyaluronic acid gel, called MaiLi. Material and methods: Like most of its competitors, MaiLi is available in various variants, including gel for filling fine wrinkles, for deeper wrinkles, folds, and for lip enhancement, in addition to gels for volumizing indications. This cohort study encompassed patients from the authors’ private esthetic clientele in Geneva, Switzerland. Depending on the indications, the injections were performed according to previously described techniques, ranging from the “blanching technique” to deeper injections. Results: Between January and November 2021, overall 45 patients aged 56 years on average were injected MaiLi gels, according to the areas they wished to be treated, with a follow-up period ranging from a few days to 12 months. Based on our current dataset, we confirm that MaiLi fillers have proven very safe, causing no unexpected undesirable effects. The gel’s hold over time related to its remarkable projection capacity was excellent, resulting in quite natural outcomes and a perfect integration into the tissues. These beneficial effects were still evident at 1-year follow-up. Conclusion: The MaiLi hyaluronic acid fillers proved to be well tolerated and safe, with long-lasting effects. Remarkable properties revealed in this follow-up were their projection capacity and suppleness, as well as their ease of use and longevity, resulting in full patient satisfaction. No relevant undesirable effects were observed. There were no edematous reactions following the injections, nor were there any lymphatic circulation disorders. Keywords: Hyaluronic acid; Volumizer gels; Skin rejuvenation; OxyFree technology
Micheels P and Poiraud M. J Clin Cosmet Dermatol 2023;7(1):1–8
Introduction The first injectable wrinkle fillers date back to 1980-1981, when bovine collagen was employed, following their approval by the American Food and Drug Administration as cosmetic drugs [1]. Given that natural Hyaluronic Acid (HA) undergoes extremely rapid turn-over within the skin, commercially available HAs needed to be cross-linked using different manufacturing techniques, resulting in products that still widely vary in formulation and cross-linking degree. Among the HAs manufactured with proprietary technologies associated with specific rheological properties, the first author already employed in the year 1994 HA prefilled syringes based on Non- Animal Stabilized Hyaluronic Acid (NASHA™, Galderma Pharma S.A., Lausanne, Switzerland) technology [2]. The first papers reporting the results obtained on subjects treated with HA gels were dated around 1998 [3,4]. Since then, numerous HA fillers have constantly been developed. Consequently, many
more brands and formulations were manufactured, some of which presenting excellent results, whereas others were less effective [5,6]. In the author’s view, several HA fillers had to be only slightly modified to drastically improve their viscoelastic properties. Moreover, lidocaine was added to certain gels, which could markedly alter the gels’ viscoelastic properties compared to their formulation without any anesthetic, as previously observed [7-9]. Recently, a novel proprietary manufacturing technology for producing innovative HA fillers was elaborated, reference being here made to MaiLi’s OxiFree™ technology (Kylane Laboratoires S.A., Plan- les-Ouates, Switzerland). This new HA filler was launched by Sinclair Pharma under the name of MaiLi. Its basic principle consists in the cross-linking of the HA under inert atmosphere and the extraction of reactive oxygen upon the manufacturing process. This procedure was primarily designed to significantly preserve the intrinsic properties of the high-molecular-weight HA chains. Based on this new technology,
1
J Clin Cosmet Dermatol | JCCD
Features Before & After Results 1 2 3 Why MaiLi
Who is MaiLi for?
MaiLi Range
Published Evidence
Product Summary
Mode of Action
MaiLi
Lanluma Ellansé
PRODUCT COMPARISON
15
Made with FlippingBook Digital Publishing Software